Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index; 10 of the 22 sources its claims cite were checked for support.

Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway

Open access
Sun, Xiaowei, Chen, Zhenhui, Yu, Lu, Zeng, Weisen, Sun, Boyuan, Fan, Hongying, Bai, Yang · 2023 · Frontiers in Pharmacology

Abstract

Background: The relationships among intestinal dysbiosis, bile acid (BA) metabolism disorders, and ulcerative colitis pathogenesis are now recognized. However, how specific strains regulate BA metabolism to alleviate colitis is still unclear. This study investigated the effects of Bacteroides dorei on the development of acute colitis and elucidated the underlying mechanisms. Methods: The safety of BDX-01 was evaluated in vitro and in vivo . 2.5% dextran sulfate sodium (DSS) induced colitis in C57BL/6 mice, Caco-2, and J774A.1 cells were used to evaluate the anti-inflammatory effect of BDX-01. qPCR and Western blotting were used to detect the expression of inflammatory pathways. Microbiota composition was analyzed by 16S rRNA gene sequencing. Enzyme activity analysis and targeted metabolomics were used to analyze fecal bile salt hydrolase (BSH) and BA levels. Antibiotic-induced pseudo-germ-free mice were used to investigate the role of gut microbiota in the alleviation of colitis by BDX-01. Results: We confirmed the safety of novel strain Bacteroides dorei BDX-01 in vitro and in vivo . Oral BDX-01 administration significantly ameliorated the symptoms and pathological damage of DSS-induced acute colitis. Moreoever, 16S rRNA sequencing and enzyme activity analysis showed that BDX-01 treatment increased intestinal BSH activity and the abundance of bacteria harboring this enzyme. Targeted metabolomics revealed that BDX-01 significantly increased intestinal BA excretion and deconjugation. Certain BAs act as FXR agonists. The β-muricholic acid (βMCA): taurine β-muricholic acid (T-βMCA) and cholic acid (CA): taurocholic acid (TCA) ratios and the deoxycholic acid (DCA) level decreased markedly in the colitis models but increased substantially in BDX-01-treated mice. The colonic farnesoid X receptor (FXR) and fibroblast growth factor 15 (FGF15) were upregulated in mice treated with BDX-01. BDX-01 downregulated the expression of colonic proinflammatory cytokines pyrin domain-containing 3 (NLRP3), ASC, cleaved caspase-1, and IL-1β. Antibiotic treatment didn’t abolish the protective effect of BDX-01 on colitis. In vitro studies showed TβMCA abolished the effects of BDX-01 on FXR activation and inhibition of the NLRP3 inflammasome activation. Conclusion: BDX-01 improved DSS-induced acute colitis by regulating intestinal BSH activity and the FXR-NLRP3 signaling pathway. Our findings indicate that BDX-01 is a promising probiotic to improve the management of ulcerative colitis.

Overview

CoChat Summary

TL;DR

Bacteroides dorei BDX-01, a strain isolated from healthy human stool, alleviated DSS-induced acute colitis in mice and showed no evident toxicity in vitro or in vivo. The paper argues that its benefit comes from increasing intestinal bile salt hydrolase (BSH) activity and activating the FXR-NLRP3 pathway, with effects also seen in cell experiments and in microbiota-depleted mice.

Key findings

  • BDX-01 was identified as a novel B. dorei strain with 99% 16S rRNA sequence similarity to B. dorei 175 and 99.97% ANI; its complete genome was 5,521,745 bp with 42.01% GC content.
  • Safety testing found no significant cytotoxicity in IEC-6 and Caco-2 cells (p > 0.05), no treatment-related toxicity in mice, and no significant differences in blood or liver/kidney indices; no histopathological injury was observed in stomach, colon, liver, or spleen.
  • In DSS colitis mice, BDX-01 reduced weight loss, colon shortening, DAI, and histopathology score; the Model group histopathology score was 8.00 ± 0.71 versus 4.80 ± 0.84 with BDX-01 and 5.40 ± 0.89 with mesalazine.
  • BDX-01 increased intestinal BSH activity and altered bile acid metabolism, including higher CA/TCA and βMCA/TβMCA ratios and higher DCA; it also upregulated colonic FXR and FGF15 and downregulated NLRP3, ASC, cleaved caspase-1, and IL-1β.
  • Antibiotic depletion of gut microbiota did not abolish protection: Abx + DSS + BDX-01 mice still had reduced body-weight loss, DAI, colon damage, and histology scores, while FXR and FGF15 increased and NLRP3/IL-1β decreased.
  • In Caco-2 cells and J774A.1 macrophages, BDX-01 suppressed TNF-α/LPS-induced Nlrp3 and Il-1β, and the effect was blocked by the FXR antagonist T-βMCA; the culture supernatant, not intact cells, upregulated Fxr and downregulated Nlrp3/Il-1β.

Methods

  • The study combined strain identification and safety profiling (16S rRNA, whole-genome sequencing, virulence/resistance annotation, antibiotic susceptibility, cell cytotoxicity, and mouse toxicity tests) with an acute DSS colitis model in C57BL/6J mice.
  • Mice received oral BDX-01, mesalazine, or controls; additional groups used antibiotic pretreatment to deplete microbiota. The paper also used Caco-2 cells and J774A.1 macrophages, plus TNF-α/LPS, FXR agonist GW4064, FXR antagonist T-βMCA, live/heat-killed bacteria, and culture supernatant.
  • Main analyses included histology, DAI, qRT-PCR, western blotting, 16S rRNA microbiome sequencing, fecal BSH activity assays, targeted bile acid metabolomics by UHPLC-MS/MS, and correlation analysis.

Limitations

  • The paper explicitly states that the acute DSS colitis model mainly reflects innate immunity and that the effect of BDX-01 on adaptive immunity will need to be explored in other IBD models.
  • The authors also state that the active components in BDX-01 responsible for the anti-colitis effect were not identified.
  • Evident from the text: the mechanistic conclusions are based on a mouse acute colitis model and cell culture experiments, so direct clinical efficacy in humans is not established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fphar.2023.1205323

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Morphological characteristics and sequence identification of BDX-01. (A) BDX-01 colonies on BHI (3% sheep blood) agar after anaerobic culture at 37°C for 48 h. (B) Gram staining under an optical microscope (×1,000). (C) Sequence identification and phylogenetic tree.
FIGURE 1 Morphological characteristics and sequence identification of BDX-01. (A) BDX-01 colonies on BHI (3% sheep blood) agar after anaerobic culture at 37°C for 48 h. (B) Gram staining under an optical microscope (×1,000). (C) Sequence identification and phylogenetic tree.CC BY · PubMed Central
FIGURE 2 BDX-01 is non-pathogenic to Caco-2 and IEC-6 cells and C57BL/6J mice. (A,B) BDX-01 cytotoxicity to Caco-2 (A) and IEC-6 (B) cells at 100:1 and 200:1 infection ratios for 4 h. The culture medium was the negative control (n = 5). (C) Changes in the BW (%)/d in the treatment and control groups. SPF C57BL/6J normal mice (n = 8) were treated with 5 × 1011 CFU/d BDX-01 for 5 days and observed for 14 days. The Control group was treated with PBS. (D) Photomicrographs of stomachs, colons, livers, and spleens of mice in the control (upper) and treatment (lower) groups. No significant lesions were observed.
FIGURE 2 BDX-01 is non-pathogenic to Caco-2 and IEC-6 cells and C57BL/6J mice. (A,B) BDX-01 cytotoxicity to Caco-2 (A) and IEC-6 (B) cells at 100:1 and 200:1 infection ratios for 4 h. The culture medium was the negative control (n = 5). (C) Changes in the BW (%)/d in the treatment and control groups. SPF C57BL/6J normal mice (n = 8) were treated with 5 × 1011 CFU/d BDX-01 for 5 days and observed for 14 days. The Control group was treated with PBS. (D) Photomicrographs of stomachs, colons, livers, and spleens of mice in the control (upper) and treatment (lower) groups. No significant lesions were observed.CC BY · PubMed Central
FIGURE 3 BDX-01 supplementation alleviated mouse DSS-induced colitis. (A) Protocol for BDX-01 supplement to mouse DSS-induced colitis model. The DSS, Mesalazine, and BDX-01 groups were administered 100 μL BHI medium or 100 μL BHI medium plus 100 μL BDX-01 culture containing 1 × 109 CFU/mL, respectively, through an intragastric cannula for 15 days. All mice received 2.5% DSS in drinking water between days 7 and 15. (B) % BW change during DSS treatment relative to baseline (day 0). (C) DAI scores during DSS treatment. (D) Representative colon morphology and length. (E) Comparison of colon lengths among the four groups. (F) Representative HE-stained histological sections (100× and 200×). (G) Comparison of colonic histopathological scores among the four groups. Statistical analysis was performed in comparison with DSS group mice. Data represent the means ± SD (n = 6–8). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (unpaired t-test, Kruskal–Wallis test, and one-way ANOVA, followed by post hoc test).
FIGURE 3 BDX-01 supplementation alleviated mouse DSS-induced colitis. (A) Protocol for BDX-01 supplement to mouse DSS-induced colitis model. The DSS, Mesalazine, and BDX-01 groups were administered 100 μL BHI medium or 100 μL BHI medium plus 100 μL BDX-01 culture containing 1 × 109 CFU/mL, respectively, through an intragastric cannula for 15 days. All mice received 2.5% DSS in drinking water between days 7 and 15. (B) % BW change during DSS treatment relative to baseline (day 0). (C) DAI scores during DSS treatment. (D) Representative colon morphology and length. (E) Comparison of colon lengths among the four groups. (F) Representative HE-stained histological sections (100× and 200×). (G) Comparison of colonic histopathological scores among the four groups. Statistical analysis was performed in comparison with DSS group mice. Data represent the means ± SD (n = 6–8). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (unpaired t-test, Kruskal–Wallis test, and one-way ANOVA, followed by post hoc test).CC BY · PubMed Central
FIGURE 4 BDX-01 mitigated DSS-induced changes in gut microbiota composition. (A) α-diversity evaluated based on the Shannon index. (B) β-diversity assessed using PCoA based on weighted UniFrac distances. (C) Average relative species-level abundances of the gut microbiota of the four mouse groups. (D) Differential species-level abundances of bacterial OTUs in the BDX-01 and DSS groups. Only differentially abundant species are shown. Data represent the means ± SD (n = 5). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.001 (one-way ANOVA, followed by post hoc test).
FIGURE 4 BDX-01 mitigated DSS-induced changes in gut microbiota composition. (A) α-diversity evaluated based on the Shannon index. (B) β-diversity assessed using PCoA based on weighted UniFrac distances. (C) Average relative species-level abundances of the gut microbiota of the four mouse groups. (D) Differential species-level abundances of bacterial OTUs in the BDX-01 and DSS groups. Only differentially abundant species are shown. Data represent the means ± SD (n = 5). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.001 (one-way ANOVA, followed by post hoc test).CC BY · PubMed Central
FIGURE 5 Treatment with BDX-01 altered the gut microbiota and BA profile and activated FXR. (A) Fecal BA profiles of the DSS and BDX-01 groups. (B) Fecal microbiota that exhibit a change in BSH activity. (C) Fecal BSH activity. (D) Total BA levels. (E) UPBA/CPBA ratio. (F) SBA/PBA ratio. (G) CA/TCA ratio. (H) βMCA/T-βMCA ratio. (I) DCA level. (J) LCA level. (K) Heatmap of correlations among predominant bacterial taxa and fecal BA in the DSS and BDX-01 groups. (L) The expression of different colonic bile acid receptors were determined using western blotting analysis. Data represent the means ± SD (n = 3–6). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. OD, optical density.
FIGURE 5 Treatment with BDX-01 altered the gut microbiota and BA profile and activated FXR. (A) Fecal BA profiles of the DSS and BDX-01 groups. (B) Fecal microbiota that exhibit a change in BSH activity. (C) Fecal BSH activity. (D) Total BA levels. (E) UPBA/CPBA ratio. (F) SBA/PBA ratio. (G) CA/TCA ratio. (H) βMCA/T-βMCA ratio. (I) DCA level. (J) LCA level. (K) Heatmap of correlations among predominant bacterial taxa and fecal BA in the DSS and BDX-01 groups. (L) The expression of different colonic bile acid receptors were determined using western blotting analysis. Data represent the means ± SD (n = 3–6). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. OD, optical density.CC BY · PubMed Central
FIGURE 6 BDX-01 regulated proinflammatory cytokine production and suppressed the NLRP3 inflammasome signaling pathway. (A) mRNA levels of Il-1β, Tnf-α, Il-6, Il-10, Nlrp3, and Caspase-1 in colon tissues were determined using qRT-PCR. (B) NF-κB, NLRP3, ASC, caspase-1, gsdmd, and IL-1β expression levels in the DSS group were determined using western blotting analysis. Data represent the means ± SD (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (unpaired t-test, Kruskal–Wallis test, and one-way ANOVA, followed by post hoc test).
FIGURE 6 BDX-01 regulated proinflammatory cytokine production and suppressed the NLRP3 inflammasome signaling pathway. (A) mRNA levels of Il-1β, Tnf-α, Il-6, Il-10, Nlrp3, and Caspase-1 in colon tissues were determined using qRT-PCR. (B) NF-κB, NLRP3, ASC, caspase-1, gsdmd, and IL-1β expression levels in the DSS group were determined using western blotting analysis. Data represent the means ± SD (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (unpaired t-test, Kruskal–Wallis test, and one-way ANOVA, followed by post hoc test).CC BY · PubMed Central
FIGURE 7 BDX-01 supplementation alleviated mouse DSS-induced colitis following antibiotic treatment. (A) Mice were administered antibiotics for 4 days to deplete the gut microbiota before DSS treatment. The Abx + DSS and Abx + BDX-01 + DSS groups were administered 100 μL culture medium and 100 μL of 1 × 109 CFU culture of BDX-01 by gavage for 15 days, respectively. (B) Body weight change, (C) disease activity index score, (D) representative images of colon and (E) colon length, (F) representative microscopic images of HE-stained sections (100×), and (G) histopathology score. (H) Fecal BSH activity. (I) FXR, FGF15, NLRP3, and IL-1β expression determined using western blotting analysis. Data are mean ± SD (n = 3–5). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (unpaired t-tests, Kruskal–Wallis test, and one-way ANOVA, followed by post hoc test).
FIGURE 7 BDX-01 supplementation alleviated mouse DSS-induced colitis following antibiotic treatment. (A) Mice were administered antibiotics for 4 days to deplete the gut microbiota before DSS treatment. The Abx + DSS and Abx + BDX-01 + DSS groups were administered 100 μL culture medium and 100 μL of 1 × 109 CFU culture of BDX-01 by gavage for 15 days, respectively. (B) Body weight change, (C) disease activity index score, (D) representative images of colon and (E) colon length, (F) representative microscopic images of HE-stained sections (100×), and (G) histopathology score. (H) Fecal BSH activity. (I) FXR, FGF15, NLRP3, and IL-1β expression determined using western blotting analysis. Data are mean ± SD (n = 3–5). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (unpaired t-tests, Kruskal–Wallis test, and one-way ANOVA, followed by post hoc test).CC BY · PubMed Central
FIGURE 8 BDX-01 downregulated the NLRP3 inflammasome and proinflammatory factors in the intestinal cells and macrophages through the FXR-dependent pathway. (A–D) mRNA levels of Nlrp3, Il-1β, Fxr, and Ibabp in Caco2 cells. Caco2 cells were pretreated with BDX-01 (MOI = 1:100), GW4064 (10 μM), and TβMCA (100 μM) for 4 h, followed by TNF-α (100 ng/mL) for 4 h. (E,F) Nlrp3, Il-1β, Fxr, and Ibabp expression in macrophages pretreated with BDX-01 (MOI = 1:100), GW4064 (10 μM), and TβMCA (100 μM) for 4 h and LPS (1 μg/mL) for 4 h. (G–I) Fxr, Nlrp3, and Il-1β expression levels in Caco2 cells. The Caco2 cells were pretreated with live BDX-01 (MOI = 1:100), heat-killed BDX-01 (MOI = 1:100), and BDS (50%) for 4 h, followed by TNF-α (100 ng/mL) for 4 h. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. n = 3 per group.
FIGURE 8 BDX-01 downregulated the NLRP3 inflammasome and proinflammatory factors in the intestinal cells and macrophages through the FXR-dependent pathway. (A–D) mRNA levels of Nlrp3, Il-1β, Fxr, and Ibabp in Caco2 cells. Caco2 cells were pretreated with BDX-01 (MOI = 1:100), GW4064 (10 μM), and TβMCA (100 μM) for 4 h, followed by TNF-α (100 ng/mL) for 4 h. (E,F) Nlrp3, Il-1β, Fxr, and Ibabp expression in macrophages pretreated with BDX-01 (MOI = 1:100), GW4064 (10 μM), and TβMCA (100 μM) for 4 h and LPS (1 μg/mL) for 4 h. (G–I) Fxr, Nlrp3, and Il-1β expression levels in Caco2 cells. The Caco2 cells were pretreated with live BDX-01 (MOI = 1:100), heat-killed BDX-01 (MOI = 1:100), and BDS (50%) for 4 h, followed by TNF-α (100 ng/mL) for 4 h. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. n = 3 per group.CC BY · PubMed Central
FIGURE 9 BDX-01 alleviates colitis by regulating the FXR/NLRP3 inflammasome signaling pathways in intestinal mucosal barriers by modulating the gut microbiota and bile acids. (A) During colitis progression, an imbalance in the gut microbiota leads to the invasion of pathogenic bacteria, such as Proteobacteria, intestinal barrier damage, macrophage infiltration, activation of intestinal epithelial cells and the macrophage inflammasome signaling pathway, and proinflammatory cytokine production. Reduction in intestinal BSH-producing bacteria alters BA unconjugation and lowers the unconjugated/conjugated primary BA ratios. Increases in conjugated BA, such as TβMCA, inhibit the farsenoid X receptor (FXR). FXR in intestinal epithelial cells and macrophages is inhibited in a BA-dependent manner, texacerbating NLRP3 inflammasome activation. (B) In the treatment of colitis, BDX-01 improves gut dysbiosis, promotes the recovery of BSH-producing bacteria, such as Firmicutes and Actinobacteria, restores gut deconjugation, increases unconjugated/conjugated primary BA ratios, and activates FXR. BDX-01 and its metabolites directly activate FXR. FXR activation in intestinal epithelial cells and macrophages suppresses the NLRP3 inflammasome activation, downregulate the proinflammatory factors, and ameliorate colitis.
FIGURE 9 BDX-01 alleviates colitis by regulating the FXR/NLRP3 inflammasome signaling pathways in intestinal mucosal barriers by modulating the gut microbiota and bile acids. (A) During colitis progression, an imbalance in the gut microbiota leads to the invasion of pathogenic bacteria, such as Proteobacteria, intestinal barrier damage, macrophage infiltration, activation of intestinal epithelial cells and the macrophage inflammasome signaling pathway, and proinflammatory cytokine production. Reduction in intestinal BSH-producing bacteria alters BA unconjugation and lowers the unconjugated/conjugated primary BA ratios. Increases in conjugated BA, such as TβMCA, inhibit the farsenoid X receptor (FXR). FXR in intestinal epithelial cells and macrophages is inhibited in a BA-dependent manner, texacerbating NLRP3 inflammasome activation. (B) In the treatment of colitis, BDX-01 improves gut dysbiosis, promotes the recovery of BSH-producing bacteria, such as Firmicutes and Actinobacteria, restores gut deconjugation, increases unconjugated/conjugated primary BA ratios, and activates FXR. BDX-01 and its metabolites directly activate FXR. FXR activation in intestinal epithelial cells and macrophages suppresses the NLRP3 inflammasome activation, downregulate the proinflammatory factors, and ameliorate colitis.CC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 1 Not valid · 7 Not checked · 82 Own results and interpretations

42 more claims

Create a free account to see all 99 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 39
  • The quote only partly states this claim. 5

Create a free account to see these claims.

Citations

Cites

Show all 64 references

Cited by

See all 33

Metadata

Authors
Sun, X., Chen, Z., Yu, L., Zeng, W., Sun, B., Fan, H., & Bai, Y.
Affiliations
  • Nanfang Hospital (CN)
  • Southern Medical University (CN)
Corresponding author
  • Fan, Hongying
  • Bai, Yang
Venue
Frontiers in Pharmacology
Published
2023-05-24
Volume
14
Pages
1205323-1205323
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4378072401
Cited by
33
References
64
Citations by year
2026: 13 · 2025: 14 · 2024: 6
FWCI
2.93
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Natural Science Foundation of Guangdong Province (2021CR008)
  • Nanfang Hospital (2021CR008)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
ulcerative colitis, DSS-induced colitis, bile salt hydrolase, bile acid metabolism, farnesoid X receptor, NLRP3 inflammasome, FGF15, gut microbiota, anti-inflammatory activity, deoxycholic acid, cholic acid, beta-muricholic acid, inflammatory cytokines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway. https://app.cochat.ai/papers/10.3389/fphar.2023.1205323
The paper
Sun, X., Chen, Z., Yu, L., Zeng, W., Sun, B., Fan, H., & Bai, Y. (2023). Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1205323

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.